Evaluation of Serum Paraoxonase, Myeloperoxidase, and HDL-Cholesterol Levels in Acute Myeloid Leukemia.
Acute myeloid leukemia
HDL-cholesterol
Myeloperoxidase
Paraoxonase
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
25
08
2023
accepted:
18
10
2023
revised:
28
09
2023
medline:
27
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
ppublish
Résumé
Inflammation and oxidative stress play a significant role in the pathogenesis of acute myeloid leukemia. While myeloperoxidase carries pro-oxidant effects, HDL-cholesterol and paraoxonase have antioxidant properties. Therefore, we evaluated serum paraoxonase, myeloperoxidase, and HDL-cholesterol levels in cases with acute myeloid leukemia. Myeloperoxidase, paraoxonase, and HDL-cholesterol levels in 40 acute myeloid leukemia patients and 18 healthy individuals were determined. The relationship between these parameters and other prognostic factors, as well as their association with response to chemotherapy, was investigated. Myeloperoxidase levels were higher, while paraoxonase and HDL-cholesterol levels were lower in acute myeloid leukemia cases compared to the control group (p < 0.001, p < 0.001, p = 0.006, respectively). The myeloperoxidase level was significantly negatively correlated with paraoxonase and HDL-c levels (r = - 0.64, p < 0.001; r = - 0.27, p = 0.02, respectively). Paraoxonase level was positively correlated with HDL level (r = 0.34, p = 0.04). Lactate dehydrogenase level was negatively correlated with HDL-c and paraoxonase levels and positively correlated with myeloperoxidase level (r = - 0.37, p = 0.019; r = - 0.35, p = 0.04; r = 0.45, p = 0.03, respectively). Following complete remission induction treatment, cases with complete remission had lower myeloperoxidase levels and higher HDL-cholesterol and paraoxonase levels compared to other cases (p = 0.03, p = 0.01, p = 0.04, respectively). Myeloperoxidase levels are higher, while paraoxonase and HDL-cholesterol levels are lower in acute myeloid leukemia cases. The obtained findings emphasize the potential importance of inflammation and oxidative stress in the pathogenesis of acute myeloid leukemia. These parameters can be used as biomarkers for prognosis prediction and prediction of response to chemotherapy.
Identifiants
pubmed: 37917329
doi: 10.1007/s10753-023-01924-0
pii: 10.1007/s10753-023-01924-0
doi:
Substances chimiques
Aryldialkylphosphatase
EC 3.1.8.1
Peroxidase
EC 1.11.1.7
Cholesterol, HDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2470-2476Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Prieto-Bermejo, R., M. Romo-González, A. Pérez-Fernández, C. Ijurko, and A. Hernández-Hernández. 2018. Reactive oxygen species in haematopoiesis: Leukaemic cells take a walk on the wild side. Journal of Experimental & Clinical Cancer Research 37 (1): 125–142.
doi: 10.1186/s13046-018-0797-0
Trachootham, D., J. Alexandre, and P. Huang. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nature Reviews. Drug Discovery 8 (7): 579–591.
doi: 10.1038/nrd2803
pubmed: 19478820
Singh, N., D. Baby, J.P. Rajguru, P.B. Patil, S.S. Thakkannavar, V.B. Pujari VB. 2019. Inflammation and cancer. Annals of African Medicine 18 (3): 121–126.
Rybicka-Ramos, M., M. Markiewicz, A. Suszka-Switek, R. Wiaderkiewicz, S. Mizia, M. Dzierzak-Mietla, and K. Bialas. 2021. Proinflammatory cytokines as potential risk factors of acute graft-versus-host disease and infectious complications after allogeneic hematopoietic stem cell transplantation. Am J Blood Res. 11 (2): 149–156.
pubmed: 34079628
pmcid: 8165716
Blatter, MC., R.W. James, S. Messmer, F. Barja, D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. European Journal of Biochemistry 211 (3): 871–879.
Deakin, S., I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R.W. James. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. Journal of Biological Chemistry 277 (6): 4301–4308.
doi: 10.1074/jbc.M107440200
pubmed: 11726658
Wang, Y., J. Zhang, Y. Hu, L. Yang, J. Xue, and Y. Ding. 2019. Relationship between paraoxonase-1 activity and lipid profiles in Chinese individuals with or without coronary artery disease. Lipids in Health and Disease. 18 (1): 45.
Mackness, MI., B. Mackness, P.N. Durrington, P.W. Connelly, R.A. Hegele. 1996. Paraoxonase: Biochemistry, genetics, and relationship to plasma lipoproteins. Current Opinion in Lipidology 7: 69–76.
Nevin, DN., A. Zambon, C.E. Furlong, R.J. Richter, R. Humbert, J.E. Hokanson, J.D. Brunzell. 1996. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 1243–1249.
Costa, LG., A. Vitalone, T.B. Cole, C.E. Furlong. 2005. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology 69: 541–550.
Baum, L., H.K. Ng, K.S. Woo, B. Tomlinson, T.H. Rainer, X. Chen, W.S. Cheung, D.K. Chan, G.N. Thomas, C.S. Tong, and K.S. Wong. 2006. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clinical Biochemistry 39: 191–195.
doi: 10.1016/j.clinbiochem.2006.01.010
pubmed: 16472799
Gokdemir, MT., A.Z. Karakilcik, G.S. Gokdemir. 2017. Prognostic importance of paraoxonase, arylesterase and mean platelet volume efficiency in acute ischaemic stroke. Journal of Pakistan Medical Association 67: 1679–1683.
Utanğaç, MM., E. Yeni, M. Savaş, A. Altunkol, H. Çiftçi, K. Gümüş, M. Demir. 2017. Paraoxonase and arylesterase activity in bladder cancer. Turkish Journal of Urology 43: 147–51.
Kul, A., H. Uzkeser, and N. Ozturk. 2017. Paraoxonase and arylesterase levels in Behcet’s disease and their relations with the disease activity. Biochemical Genetics 55: 335–344.
doi: 10.1007/s10528-017-9800-2
pubmed: 28389737
Khan, AA., M.A. Alsahli, A.H. Rahmani. 2018. Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives. Medical Sciences (Basel) 6 (2): 33.
Anatoliotakis, N., S. Deftereos, G. Bouras, G. Giannopoulos, D. Tsounis, C. Angelidis, A. Kaoukis, and C. Stefanadis. 2013. Myeloperoxidase: Expressing inflammation and oxidative stress in cardiovascular disease. Current Topics in Medicinal Chemistry 13 (2): 115–138.
doi: 10.2174/1568026611313020004
pubmed: 23470074
Ajila, V., V. Ravi, S. Kumari, S. Babu, S. Hegde, and A. Madiyal. 2015. Serum and salivary myeloperoxidase in oral squamous cell carcinoma: A preliminary study. Clin Cancer Investig J. 4 (3): 344–348.
Lai, WM., C.C. Chen, J.H. Lee, C.J. Chen, J.S. Wang, Y.Y. Hou, H.H. Liou, H.C. Chen, T.Y. Fu, Y.C. Lee, L.P. Ger. 2013. Second primary tumors and myeloperoxidase expression in buccal mucosal squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology 116 (4): 464–473.
Qin, X., Y. Deng, Z.Y. Zeng, Q.L. Peng, X.L. Huang, C.J. Mo, S. Li, and J.M. Zhao. 2013. Myeloperoxidase polymorphism, menopausal status, and breast cancer risk: An update meta-analysis. PLoS ONE 8 (8): e72583.
doi: 10.1371/journal.pone.0072583
pubmed: 23991124
pmcid: 3749128
Arslan, S., H. Pinarbasi, and Y. Silig. 2011. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Molecular Medicine Reports 4 (1): 87–92.
pubmed: 21461569
Jilani, I., T. Vincenti, H. Faraji, F.J. Giles, E. Estey, H.M. Kantarjian, and M. Albitar. 2004. Clinical relevance of circulating myeloperoxidase (MPO) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 104 (11): 1073.
doi: 10.1182/blood.V104.11.1073.1073
Gonçalves, RP., D.G. Rodrigues, R.C. Maranhão. 2005. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leukemia Research 29 (8): 955–959.
Kuliszkiewicz-Janus, M., R. Małecki, and A.S. Mohamed. 2008. Lipid changes occuring in the course of hematological cancers. Cellular & Molecular Biology Letters 13: 465–474.
doi: 10.2478/s11658-008-0014-9
Rye, KA., C.A. Bursill, G. Lambert, F. Tabet, P.J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research 50: 195–200.
Undurti, A., Y. Huang, J.A. Lupica, J.D. Smith, J.A. DiDonato, and S.L. Hazen. 2009. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. Journal of Biological Chemistry 284 (45): 30825–30835.
doi: 10.1074/jbc.M109.047605
pubmed: 19726691
pmcid: 2781481
Eckerson, EW., J. Romson, C. Wyte, B.N. La Du. 1983. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. American Journal of Human Genetics 35: 214–227.
Bradly, PP., D.A. Priebat, R.D. Christensen, G. Rathstein. 1982. Measurement of cutaneous inflammations estimation of neutrophil content with an enzyme marker. Journal of Investigative Dermatology 78 (3): 206–209.
Akçay, MN., I. Yilmaz, M.F. Polat, G. Akçay. 2003. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50: cclxxiii-cclxxv.
Elkiran, ET., N. Mar, B. Aygen, F. Gursu, A. Karaoglu, S. Koca. 2007. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 15: 48.
Samra, ZQ., S. Pervaiz, S. Shaheen, N. Dar, M.A. Athar. 2011. Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1) enzymes and lipid parameters in different cancer patients. Clinical Laboratory 57 (9–10): 741–747.
Çebi, A., E. Akgun, R. Esen, H. Demir, and A. Çifci. 2015. The activities of serum paraoxonase and arylesterase and lipid profile in acute myeloid leukemia: Preliminary results. European Review for Medical and Pharmacological Sciences 19 (23): 4590–4594.
pubmed: 26698256
Bacchetti, T., G. Ferretti, and A. Sahebkar. 2019. The role of paraoxonase in cancer. Seminars in Cancer Biology 56: 72–86.
doi: 10.1016/j.semcancer.2017.11.013
pubmed: 29170064
Morsia, E., S. Rupoli, E. Molinelli, D. Sartini, A.M. Ofdani, M. Emanuelli, E. Salvolini, A. Olivieri, and G. Goteri. 2021. Expression of paraoxonase-2 in different stages of cutaneous T cell lymphoma: Is it a potential biomarker for aggressiveness? Blood 138: 4496–4497.
doi: 10.1182/blood-2021-150793
Ellidag, HY., E. Eren, O. Aydin, M. Yıldırım, C. Sezer, N. Yilmaz. 2014. Multiple myeloma: Relationship to antioxidant esterases. Medical Principles and Practice 23 (1): 18–23.
Musolino, C., L. Calabrò, G. Bellomo, M. Cincotta, V. Di Giacomo, C. Pezzano, B. Loteta, V. Rizzo, S. Guglielmo, and A. Alonci. 2002. Lipid profile in hematologic neoplasms. Rec Prog Med. 93: 298–301.
Lim, U., T. Gayles, H.A. Katki, R. Stolzenberg-Solomon, S.J. Weinstein, P. Pietinen, P.R. Taylor, J. Virtamo, and D. Albanes. 2007. Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Research 67 (11): 5569–5574.
doi: 10.1158/0008-5472.CAN-07-0212
pubmed: 17522388
Fiorenza, AM., A. Branchi, D. Sommariva. 2000. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. International Journal of Clinical and Laboratory Research 30 (3): 141–145.
Baroni, S., D. Scribano, C. Zuppi, L. Pagano, G. Leone, and B. Giardina. 1996. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematologica 96 (1): 24–28.
doi: 10.1159/000203710
pubmed: 8677757
Wang, L., P.D. Chi, H. Chen, J. Xiang, Z.J. Xia, and Y.J. Zhang. 2014. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumour Biology 35 (3): 2141–2149.
doi: 10.1007/s13277-013-1284-z
pubmed: 24122233